PCM
ODT

Penserra Capital Management’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Penserra Capital Management’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-880
Closed -$2K – 1639
2021
Q3 		$2K Buy
880
+5
+0.6% +$17 ﹤0.01% 1439
2021
Q2 		$3K Hold
875
– – ﹤0.01% 1331
2021
Q1 		$2K Sell
875
-10
-1% -$189 ﹤0.01% 1104
2020
Q4 		$16K Buy
+885
New +$13.7K ﹤0.01% 881

Other funds holding ODT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MA
MYDA Advisors Woodmere, New York $608M AUM 77.08% 1-Year Est. Return

Penserra Capital Management's ODT Position: Q4 2021 in Review

Penserra Capital Management sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q4 2021, closing a stake of 880 shares — an estimated $2K sold.

Penserra Capital Management first reported a position in ODT in Q4 2020 and held it in 4 quarters. The position peaked at $16K in Q4 2020. 50 funds tracked by Wall St. Rank hold ODT as of Q4 2021.

  • Penserra Capital Management reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 880 Odonate Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $2K.
  • Penserra Capital Management first reported a position in Odonate Therapeutics, Inc. Common Stock in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's Odonate Therapeutics, Inc. Common Stock position peaked at $16K in Q4 2020.
  • 50 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.